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Abstract
Background: Rab25, a member of Rab family of small guanosine triphosphatase, is associated with progression
of various types of human cancers, including lung cancer, the leading cause of cancer-associated deaths around
the globe.
Methods: In this study, we report the gene therapeutic effect of short hairpin Rab25 RNA (shRab25) on
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. In-
itially, mice (6 weeks old) were injected with single dose of NNK (2 mg/0.1 mL saline/mouse) by intraperi-
toneal injection to induce the tumor. Eight weeks later, shRab25 was complexed with glycerol propoxylate
triacrylate-spermine (GPT-SPE) copolymer and delivered into tobacco-induced lung cancer models through a
nose-only inhalation system twice a week for 2 months.
Results: GPT-SPE/shRab25 largely decreased the tobacco-induced tumor numbers and tumor volume in the
lungs compared to GPT-SPE- or GPT-SPE/shScr-delivered groups. Remarkably, aerosol-delivered GPT-SPE/
shRab25 significantly decreased the expression level of Rab25 and other prominent apoptosis-related proteins in
female A/J mice. The apoptosis in these mice was determined by detecting the expression level of Bcl-2,
proliferating cell nuclear antigen, Bax, and further confirmed by TUNEL assay.
Conclusions: Our results strongly confirm the tumorigenic role of Rab25 in tobacco carcinogen-induced lung
cancer and hence demonstrate aerosol delivery of shRab25 as a therapeutic target for lung cancer treatment.
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Introduction
Lung cancer is the main cause of cancer-related deathsin the world (1.6 million, 19.4%), and the development
of more effective lung cancer therapy still remains chal-
lenging.(1) In fact, 80%–90% of lung cancers are strongly
associated with tobacco smoking. Among the thousands
of carcinogenic compounds found in tobacco products,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is
the main player to lung carcinogenesis.(2,3)
Rab25 belongs to the Rab-related small guanosine tri-
phosphatase (GTPases) proteins; these proteins are consid-
ered key regulators of intracellular membrane trafficking
involved in various diseases, including cancer.(4,5) Several
Rab GTPases, including Rab25, have been examined for
being potential drivers in carcinogenesis.(6) Studies have
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shown that Rab25 contributes to the aggressiveness of breast
and ovarian cancers.(7) Notably, knockdown of Rab25 ex-
pression inhibits the growth of ovarian cancer cells,(8) in-
dicating the essential role for RAB25 in tumor progression
and aggressiveness.(9) Specifically, knockdown of Rab25 by
small interfering RNA (siRNA) suppressed cell migration
and invasion in nonsmall-cell lung carcinoma (NSCLC)
cells.(10) While RAB25 expression is positively correlated
with E-cadherin, it is negatively associated with ZEB1 in
NSCLC cell lines.(11) Particularly, the effects of Rab25
knockdown on tumor proliferation and apoptosis were
confirmed in mice xenografted with gefitinib-sensitive lung
cancer cells.(12)
Many scientists have therefore largely focused on RNA
interference (RNAi)-based knockdown for cancer therapy.
Usually, two kinds of RNAi-based therapeutics are well
known: a vector-based short hairpin RNA (shRNA) or a
chemically synthesized double-stranded siRNA.(13) A
number of studies have been conducted with several RNAi-
based therapies, such as shSCRN1 in lung cancer cell
lines,(14) siDDR1in cancer cell lines,(15) shCul4A in lung
cancer cells,(16) and short hairpin Rab25 RNA (shRab25) in
colon cancer cell lines.(17) In comparison with other meth-
ods, shRNA has demonstrated great potential as a promising
tool for cancer treatment.
Aerosol-mediated gene delivery performs a noninvasive
alternative for the targeting of genes to the lungs.(18) In this
regard, we have previously used several nonviral or viral
vectors to transport DNA or siRNA or shRNA through
aerosol delivery for lung cancer treatment.(19) For example,
we delivered shAkt1 by glycerol triacrylate-spermine (GT-
SPE) to suppress lung cancer progression.(20) Similarly, we
used polyspermine to deliver the Pdcd4 gene that greatly
reduced tumor size in K-rasLA1 lung cancer model mice.(21)
Also, we have successfully used aerosol delivery of RNAi-
based therapeutics by various polymer complexes, including
spermine-based poly(amino ester)/Akt1shRNA complexes,(22)
folate–chitosan-graft polyethylenimine/Akt1 shRNA com-
plexes,(23) and poly(ester amine)/Akt1 siRNA complexes.(24)
Using lentivirus as a viral vector, several shRNAs, such
as AIMP2-DX2 shRNA,(25) OPN shRNA,(26) and PDCD4
shRNA,(27) were used for lung cancer treatments through
aerosol delivery.
In this study, we delivered shRab25 in NNK-induced lung
tumorigenesis female A/J mice through aerosol delivery to




NNK was purchased from Toronto Research Chemicals,
Inc. (Toronto, Canada). Rab25 antibody was purchased from
Abcam (Cambridge, United Kingdom). a-Tubulin from
AbFrontier (Seoul, Korea); Bax, Bcl-2, and proliferating cell
nuclear antigen (PCNA) antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The Dead-
End Colorimetric TUNEL assay kit was obtained from
Promega Corporation (Madison, WI). Rab25 shRNA
(shRab25) and the scrambled control shRNA (shScr) were
purchased from Koram Biogen Corp. (Korea).
Mouse experiment
Female A/J mice, 5 weeks old, weighing 15–19 g, were re-
ceived from Central Laboratory Animal, Inc. (Seoul, Korea).
Mice were housed under a standard light/dark cycle at a stable
temperature (23C – 2C) and relative humidity (50% – 10%)
in the laboratory animal facility. The mice, 6 weeks of age,
were divided into five groups, each group containing eight
mice. Four groups of mice were injected with single dose of
NNK (2 mg/0.1 mL saline/mouse) through intraperitoneal (IP)
route. For gene delivery, three groups (except NNK control and
saline control group) of mice were exposed with the Rab25
complexes in the nose-only inhalation chamber as described
previously.(28,29) The polymer complex with DNA (shScr or
shRab25) or aerosol containing polymer only was delivered 16
times (twice a week for eight consequent weeks). Mice were
sacrificed 1 week after exposure and tumors on lung surface
were carefully counted, as mentioned previously.(30) Finally,
collected lungs were fixed in 10% formalin for histopatho-
logical examination and remaining lungs stored at -70C for
further experiments. All animal experiments were approved by
the Animal Care and Use Committee at Seoul National Uni-
versity (SNU-140814-3).
Construction of Rab25 shRNA and preparation
of GPT-SPE/shRNA complex
The shRNA sequence targeting mouse Rab25 mRNA and
scrambled control were purchased. The glycerol propoxylate
triacrylate-spermine (GPT-SPE) copolymer was synthesized
as described previously.(22) GPT-SPE/shRNA complexes
were self-assembled in distilled water by slow adding of
0.8 mg of DNA to 8 mg of polymer solution under gentle
mixing. The complexes (final volume 30 mL) were incubated
for 30 minutes at room temperature (RT) before delivery.
Western blot analysis
Lung tissues were lysed with the IKA T10 homogenizer
(IKA; Works GmbH & Co., Staufen, Germany) to extract
the proteins. Total protein concentration was confirmed by
using the Pierce BCA reagent (Thermo Scientific). Equal
amounts (25 lg/well) of protein were loaded into 10%–12%
sodium dodecyl sulfate–polyacrylamide gels and transferred
to nitrocellulose membranes using the iBlot system (Life
Technologies, Grand Island, NY). Membranes were blocked
with Tris-buffered saline with Tween 20 (TTBS) containing
5% skim milk for 1 hour at RT, and immunoblotting was
performed by incubation overnight at 4C with the corre-
sponding primary antibodies. The following day, antibody
was labeled with secondary horseradish peroxidase (HRP)
for 4 hours at RT. After washing, bands were captured using
a model EZ-capture MG luminescent image detector
(ATTO, Tokyo, Japan) and analyzed by using ATTO CS
Analyzer windows version 3.0 (ATTO).
Histopathologic and immunohistochemistry analysis
Paraffin-embedded and sectioned lung tissues (4 lm) were
stained by hematoxylin and eosin. For immunohistochemistry
(IHC) analysis, the lung sections were then deparaffinized in
xylene (each for 5 minutes · 2 times), rehydrated by alcohol
gradients (2 min/each), and then washed with distilled water
and 3% hydrogen peroxide, used for 10 minutes of incubation.

























































To block the unspecific binding sites, sections were incubated
with 3% bovine serum albumin in TTBS for 1 hour at RT after
washing with a TTBS solution. Concerned primary antibodies
(1:100) were used overnight at 4C. Next day, the samples
were rinsed by TTBS and then incubated in secondary anti-
bodies conjugated to HRP (1:200) for 3 hours at RT. Then,
3,3¢-diaminobenzidine (DAB) reagent (Life Technologies)
was reacted with the tissue sections, and these were analyzed
by light microscopy. The tissue sections were counterstained
with a Mayer’s hematoxylin (DAKO, Carpinteria, CA) and
mounted using cover slide and the Permount (Fisher Scien-
tific, Waltham, MA). The slides were observed using a Nikon
eclipse fluorescence microscope (Tokyo, Japan).
Analysis of apoptotic cells by TUNEL assay
Determination of apoptotic cells using the DeadEnd Col-
orimetric TUNEL assay kit and all steps according to kit’s
instructions. Briefly, for paraffin-embedded lung tissues,
sections were deparaffinized and rehydrated by xylene or
graded ethanol (100%, 85%, 70%, and 50%) at RT, respec-
tively. The rTdT reaction mix is added on equilibrated areas
and incubated at 37C for 60 minutes. After several washes in
PBS and 2X SSC, the slides were incubated with streptavidin-
HRP solution for 30 minutes at RT. For counterstaining
procedure, DAB substrate was added to each slide and de-
veloped until the appearance of light brown background.
Slides were observed by a light microscope to select · 1000
magnification fields (Olympus BX51, Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using Student’s t-test
with Microcal Origin (Microcal Software, Northampton).
Results are expressed as mean values – standard errors of
three independent experiments (n = 3). All data were com-
pared with corresponding values ( p < 0.001 was more sig-
nificant, p < 0.01 was highly significant, and p < 0.05 was
considered statistically significant).
Results
In vivo aerosol delivery of shRab25
To determine the carcinogenic function of NNK in vivo,
mouse experiment was designed as illustrated in Figure 1A.
The mice, 6 weeks of age, were divided into five groups, each
group containing eight mice. Four groups of mice were in-
jected with single dose of NNK (2 mg/0.1 mL saline/mouse)
FIG. 1. (A) Experimental design of tumor induction and treatment. Six-week-old mice
(eight mice/group) were injected intraperitoneally with NNK (100 mg/kg). At 22 weeks, mice
were sacrificed and lungs were harvested for evaluation of lung tumors. (B) Body weight of
mice from 14 to 21 weeks during aerosol delivery (n = 5, *p < 0.05 saline compared to
NNK+GPT-SPE only, NNK+GPT-SPE/shScr, and NNK+GPT-SPE/shRab25). GPT-SPE,
glycerol propoxylate triacrylate-spermine; shRab25, short hairpin Rab25 RNA.

























































through IP.(31) Single IP injection of NNK for lung tumori-
genesis in A/J mice is a simple procedure that takes 16 weeks
for a reasonable yield of lung tumors to develop.(32) The ex-
periment was carried out with one group of mice that were
treated with an equal volume of saline (vehicle control of
NNK). Eight weeks later, the NNK-treated mice were ex-
posed with GPT-SPE, GPT-SPE/shScr, and GPT-SPE/
shRab25 for 16 times (twice a week for eight consecutive
weeks). Body weights of individual mouse were recorded
weekly for 8 weeks during the aerosol delivery (Fig. 1B).
Aerosol delivery of Rab25 shRNA suppresses
tumorigenesis in lung
As shown in Figure 2A, the injection of NNK induced a
number of tumors in lungs, while there was no such tumor
growth in lungs of control group mice (saline). After aerosol
delivery of GPT-SPE, GPT-SPE/shScr, and GPT-SPE/
shRab25 in NNK-induced A/J mice for 8 weeks, we found
that GPT-SPE/shRab25 largely decreased the tobacco-
induced tumor numbers in the lungs compared to GPT-SPE-
or GPT-SPE/shScr-delivered groups. The observed antitumor
effects of GPT-SPE/shRab25 are illustrated graphically
(Fig. 2B, C, and Table 1). The results showed that aerosol-
delivered GPT-SPE/shRab25 complex significantly decreased
lung tumor number (n = 5) (Fig. 2B) and tumor volume (n = 5)
(Fig. 2C). For further confirmation of antitumor effect of
aerosol-delivered GPT-SPE/shRab25 complex, we performed
the histopathologic analysis of lung tissues of mice 8 weeks
after the aerosol delivery (Fig. 2D). The results demonstrated
the higher tumor suppression effect of GPT-SPE/shRab25
than other GPT-SPE- or GPT-SPE/shScr-treated groups.
Cell proliferation was suppressed in aerosol
delivery of shRab25
To evaluate cell proliferation in tumor tissue, IHC and
western blot studies were performed. Western blot results
confirmed that aerosol-delivered GPT-SPE/shRab25 group
had very low levels of PCNA expression than GPT-SPE or
GPT-SPE/shScr groups (Fig. 3A). Further densitometry
analyses revealed that the expression level of PCNA in
GPT-SPE/shRab25 group was significantly lower than other
groups (Fig. 3B). We also investigated the expression level
of PCNA by IHC. The experimental results demonstrated
the clear evidence of lower expression of PCNA in GPT-
SPE/shRab25 group (Fig. 3C). In addition, PCNA counting
analysis showed that delivery of GPT-SPE/shRab25 signif-
icantly decreased PCNA-positive cells compared to the
NNK control, NNK+GPT-SPE-only, and NNK+GPT-SPE/
shScr groups (Fig. 3D).
Downregulation of Rab25 induced apoptotic
cell death in lung cancer
To determine the expression level of Rab25 in the A/J
mice lungs of NNK-treated A/J mice after inhalation of
shRab25, western blot analysis was accomplished. Western
FIG. 2. Therapeutic efficiency of shRab25 through aerosol delivery in A/J mice. (A) Lung tumor lesions. (B) Total tumor
numbers (n = 5, ***p < 0.001 compared to NNK control, **p < 0.01 compared to NNK+GPT-SPE only and NNK+GPT-SPE/
shScr). (C) Total tumor volume (**p < 0.01 compared to NNK control and NNK+GPT-SPE/shScr). (D) Histopathological
features (magnification, 100 · and 200 · ).

























































blot result clearly demonstrated that the expression level of
Rab25 after inhalation of GPT-SPE/shRab25 in the NNK-
induced A/J mice largely decreased when compared to only
NNK-treated A/J mice (Fig. 4A). Quantification of the
western blot further confirmed the low expression of Rab25
in the GPT-SPE/shRab25-delivered group (n = 3, p <0.05
compared with NNK control) (Fig. 4B). To corroborate the
induction of apoptosis by aerosol delivery of GPT-SPE/
shRab25, we investigated the expressions of Bax (a proa-
poptotic protein) and Bcl-2 (an antiapoptotic protein) pro-
teins in lung tissues by western blot. The results showed that
the level of Bcl-2 decreased significantly in the GPT-SPE/
shRab25-delivered group (n = 3) than other controls. In
contrast, the level of Bax increased in the GPT-SPE/
shRab25-delivered group (n = 3) than other groups (Fig. 4C
and E). Furthermore, detection of apoptosis by TUNEL
assay also indicated the higher amount of TUNEL-positive
cells in the NNK+GPT-SPE/shRab25 group (Fig. 4F).
Discussion
Lung cancer is the leading cause of cancer deaths
worldwide, especially due to tobacco smoking that causes
nearly 6 million deaths per year. Tobacco contains a variety
of carcinogens, of which NNK has been identified as the
most potent lung carcinogen.(33) It is noted that a single IP
injection of NNK at a dose of 2 mg is enough to induce an
average of 10–12 lung adenomas per A/J mouse.(34) Hence,
A/J mouse is a suitable model to study the molecular
mechanisms of NNK to induce the development and pro-
gression of lung tumors. Based on these animal models,
although many antitumor agents have been identified to
suppress NNK-induced lung carcinogenesis to some extent,
it is still necessary to develop advanced methods to treat
lung cancer at the genetic level.
It has been reported that chromosome instability, genetic
mutation, and activation of oncogenes occurred in NNK-
induced lung tumors due to disruption of the expression of
several enzymes of various cellular signaling pathways.(35)
Rab25 signaling pathway plays a role in the regulation of
cell proliferation and apoptosis in cancer cells, indicating
that the Rab25 gene plays an important role in tumor oc-
currence and development.(36) Previous in vitro studies re-
ferred that downregulation of Rab25 has a large effect on
cancer suppression and indicated that Rab25 could be an
essential molecular target for cancer therapy.(37–39) Con-
sidering gene therapy as a promising treatment strategy for
cancer, aerosol delivery of therapeutic genes seems the most
convenient way for lung cancer gene therapy because it is a
simple, noninvasive, and direct method that makes instant
Table 1. Summary of Tumor Incidence in NNK-Induced A/J Mice After Aerosol Therapy
Group Mice identification No. of adenocarcinomas No. of adenomas No. of hyperplasia foci
NNK control 1 4 2 1
2 4 1 1
3 2 1 3
4 3.33 0 0
5 3.5 3 3
Average 3.36 1.4 1.6
STD 0.82 1.14 1.34
NNK+GPT-SPE only 1 1 0 2
2 3 1 2
3 3 1 0
4 4 2 3
5 3 1 2
Average 2.8 1 1.8
STD 1.10 0.71 1.10
NNK+GPT-SPE/shScr 1 3 1 1
2 3 1 2
3 3.5 1 2
4 3 0 2
5 3 2 3
Average 3.1 1 2
STD 0.22 0.71 0.63
NNK+GPT-SPE/shRab25 1 1 1 2
2 2 0 0
3 2 2 2
4 1 0 3
5 1 0 0
Average 11.4**,#,{{{ 0.6 1.4
STD 0.55 0.89 1.34
GPT-SPE, glycerol propoxylate triacrylate-spermine; NNK only, mice induced with NNK as a positive control; NNK+GTP-SPE only,
mice induced with NNK and treated with GPT-SPE copolymer; NNK+GTP-SPE/shScr, mice induced with NNK and treated with GPT-
SPE/shScr complex; NNK+GTP-SPE/shRab25, mice induced with NNK and treated with GPT-SPE/shRab25 complex; shRab25, short
hairpin Rab25 RNA; STD, standard deviation.
**p < 0.01 compared to NNK group.
#p < 0.05 compared to GPT-SPE only.
{{{p < 0.001 compared to GPT-SPE/shScr.

























































access to lungs without any effect to other organs due to the
anatomical structure and location of the lungs inside the
body.(40)
Besides, the large surface area, good vascularization, and
ultrathin structure of the alveolar epithelium are distinctive
features of the lung that can facilitate systemic delivery via
pulmonary route.(41) Moreover, aerosol particles can reach
the gas-exchange surfaces of the alveolar region of the
lung,(42) rendering the pulmonary route as an attractive
pathway for aerosol delivery. Recently, aerosol delivery of
polyethyleneimine (PEI) complexes of p53 and IL-12 genes
stimulated higher therapeutic responses in different animal
lung tumor models.(40,43) PEI usually forms stable com-
plexation with DNA to protect DNA from degradation and
stable during nebulization. Although PEI has been known to
be an efficient vector for gene delivery both in vitro and
in vivo, it exerts some degree of cytotoxicity when admin-
istered to the body.
In pursuit of low-toxic gene carrier, researchers have
made a number of polymers based on PEI backbone to re-
duce the cytotoxic property of gene carrier. In fact,
spermine-based poly(amino ester)/DNA complexes are less
FIG. 3. Inhibition of cell proliferation by aerosol delivery of shRab25. (A) Western blot
analysis of PCNA. (B) Quantification of PCNA expression. Bands were analyzed by
densitometer (n = 3, **p < 0.01 compared to NNK control, NNK+GPT-SPE only, and
NNK+GPT-SPE/shScr, #p < 0.05 compared to saline control). (C) PCNA immunohisto-
chemistry analysis (magnification, 400 · ). (D) PCNA counting (n = 3, **p < 0.01 compared
to NNK control, ***p < 0.001 compared to GPT-SPE only, and GPT-SPE/shScr, ###p < 0.001
compared to saline control, ##p < 0.01 compared to saline control), PCNA, proliferating cell
nuclear antigen.

























































FIG. 4. Determination of apoptosis mechanism by aerosol delivery of shRab25. (A, C)
Western blot analysis. Statistical analysis of western blot (B) Rab25 (n = 3, **p < 0.01
compared to NNK control). (D) Bcl-2 (n = 3, *p < 0.05 compared to NNK control,
NNK+GPT-SPE only, NNK+GPT-SPE/shScr, #p < 0.05 compared to saline control). (E) Bax


























































toxic than PEI 25K-based complexes. In this study, we
therefore used spermine, a short homologue of PEI, in
combination with glycerol, to prepare a biodegradable co-
polymer (GPT-SPE) as a gene delivery carrier. Particularly,
GPT-SPE had low cytotoxicity and it exhibited high ability
to form a complex with DNA. Besides, the physicochemical
and biological characterizations of GPT-SPE exhibited it as
a safe and efficient gene delivery carrier. Consequently,
GPT-SPE efficiently delivered shRNA through the aerosol
route for lung cancer gene therapy.(22) Since the properties
of GPT-SPE deemed safe and efficient, we selected GPT-
SPE to deliver DNA, especially shRNA to downregulate
Rab25 in lung cancer through the RNAi mechanism.
Fortunately, the emergence of RNAi phenomenon has
provided new opportunities for cancer therapy. Particularly,
shRNAs that enable persistent suppression of sequence-
specific gene silencing show great promise for therapeutic
applications. Accordingly, our research group has used vari-
ous polymers to deliver Akt1 shRNAs (shAkt1) by aerosol
route for in vivo lung cancer therapy. For example, we used
folate–chitosan-graft-PEI to deliver shAkt1to suppress the
lung tumorigenesis in male A/J mice.(23) In another study,
GT-SPE/shAkt1complex suppressed lung tumorigenesis in a
K-rasLA1 lung cancer mouse model by inducing apoptosis
through the Akt signaling pathway and cell cycle arrest.(20)
Similarly, aerosol delivery of GPT-SPE/shAkt1complexes
greatly suppressed lung tumorigenesis in the K-rasLA1 lung
cancer mouse models.(22)
Considering that apoptosis induction by shRNA would be
an efficient and promising strategy for cancer gene therapy,
we determined to evaluate the effect of Rab25 shRNA in lung
tumorigenesis through aerosol delivery. Importantly, down-
regulation of Rab25 by shRNA exhibited proliferation, in-
duced apoptotic cell death, and then decreased tumor growth
in ovarian cancer xenograft mouse.(8) In this study, we used
female A/J mice to observe in vivo effects of aerosol-
delivered Rab25 shRNA in lung tumorigenesis because fe-
male A/J mice are more sensitive to NNK-induced lung car-
cinogenesis than males.(44) We took advantage of our potent
gene carrier, GPT-SPE, to deliver shRNA for lung tumor
therapy. As expected, aerosol delivery of GPT-SPE/shRab25
complexes in the female A/J mice showed remarkable anti-
cancer effects. The total tumor number and tumor volume of
lung surface neoplastic lesions were significantly decreased
after repeated aerosol delivery of shRab25. Similarly, the
nodules (adenocarcinoma and adenoma) and their numbers
were comparably smaller in the lungs of NNK+GPT-SPE/
shRab25-treated mice group than in the lungs of mice treated
with NNK control, NNK+GPT-SPE/shScr, and NNK+GPT-
SPE-only groups (Table 1).
Notably, the aerosol delivery of GPT-SPE/shRab25 lar-
gely decreased the PCNA expression levels, as detected by
IHC and western blot. The PCNA protein plays a great role
in the process of life and death of the cell. Usually, apo-
ptosis occurs when PCNA is absent or present in low
quantities in the cell.(45) The decreased level of PCNA in the
GPT-SPE/shRab25 group was thus an indication of antitu-
mor effect of shRab25. These data clearly demonstrated that
delivery of shRab25 reduced cell proliferation in the NNK-
induced lung tissue. Consistently, aerosol-delivered GPT-
SPE/shRab25 decreased Rab25 expression levels as exam-
ined by densitometric analysis and western blot. Besides,
our in vivo study revealed that GPT-SPE/shRab25 induced
apoptotic cell death, associated with Bcl-2 downregulation
and Bax upregulation, which is a well-known phenomenon
of a mitochondria-mediated apoptosis pathway where Bax is
translocated to the mitochondria from cytosol through the
reduction of Bcl-2. To further assess the suppression of lung
cancer progression by shRab25, associated with apoptosis
proteins, we performed TUNEL assay to detect the abun-
dance of apoptosis-related proteins in the lung tissues. The
TUNEL assay confirmed the higher number of TUNEL-
positive cells in the NNK+GPT-SPE/shRab25 group than
other controls. These data exhibited that shRab25 could
facilitate apoptosis in the lungs of NNK-induced A/J mice.
In summary, the present investigation demonstrated that
aerosol delivery of shRab25 complex efficiently suppressed
the tobacco carcinogen-induced lung cancer. Thus, this
study confirmed that the aerosol delivery system could offer
a promising approach for specific delivery of shRNA as an
effective tobacco carcinogen-induced lung cancer therapy.
To our best knowledge, this study is the first demonstration
of the treatment of tobacco carcinogen-induced lung tu-
morigenesis in A/J mice by using Rab25 shRNA.
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